Suppr超能文献

洛贝林二钠抑制组成型 NO-cGMP 代谢途径。可能作为免疫调节药物参与其中。

Lobenzarit disodium inhibits the constitutive NO-cGMP metabolic pathways. Possible involvement as an immunomodulatory drug.

机构信息

Center of Pharmaceutical Chemistry Department of Pharmacology and Toxicology Havana City POB 6990 Cuba.

出版信息

Mediators Inflamm. 1995;4(5):364-7. doi: 10.1155/S0962935195000597.

Abstract

Lobenzarit disodtulIl (CCA) is a novel immunomodulatory drug useful in the treatment of chronic inflammations. Its principal mechanism of action seems to be through enhancing the T suppressor/T helper lymphocyte ratio. However, the molecular basis for these actions remains unclear. In this study it was found that CCA inhibits the production of guanosine 3',5'-cyclic monophosphate almost completely when present in concentrations of 1 mM. Further results demonstrated that such inhibition could also be explained by interference in constitutive nitric oxide generation. In addition to previous findings, more insight into the molecular mechanism of action of CCA is provided.

摘要

洛贝沙替丁二钠(CCA)是一种新型的免疫调节药物,可用于治疗慢性炎症。其主要作用机制似乎是通过增强 T 抑制/T 辅助淋巴细胞比值。然而,这些作用的分子基础尚不清楚。本研究发现,当浓度为 1mM 时,CCA 几乎完全抑制鸟苷 3',5'-环单磷酸的产生。进一步的结果表明,这种抑制也可以通过干扰固有一氧化氮的产生来解释。除了以前的发现外,本研究还进一步深入了解了 CCA 的作用机制。

相似文献

2
Regulation of B cell function by lobenzarit, a novel disease-modifying antirheumatic drug.
Arthritis Rheum. 1992 Feb;35(2):168-75. doi: 10.1002/art.1780350208.
10
Anti-oxidative profile of lobenzarit disodium (CCA).
Biochem Pharmacol. 1990 Nov 1;40(9):2117-22. doi: 10.1016/0006-2952(90)90243-e.

本文引用的文献

6
Inhibition of streptozocin-induced insulitis and diabetes with lobenzarit in CD-1 mice.
Diabetes. 1989 May;38(5):558-61. doi: 10.2337/diab.38.5.558.
10
Anti-oxidative profile of lobenzarit disodium (CCA).
Biochem Pharmacol. 1990 Nov 1;40(9):2117-22. doi: 10.1016/0006-2952(90)90243-e.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验